Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

772219

registered interest
date	17/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to assess the (a) clinical benefit and (b) value for money of Endaravone in extending the lifespan of people with motor neurone disease.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	108151
answer	answer is ministerial correction date of answer 25/10/2017 answer text <p>We have assumed the Hon. Member is referring to edaravone (Radicava). Edaravone is not currently licensed or under assessment within the European Union for any indication and the Department therefore has no such plans. If the manufacturer seeks a marketing authorisation for edaravone in the United Kingdom or EU, it will be assessed for safety, efficacy and quality through the established licensing process and then considered through the topic selection process for possible assessment of clinical and cost effectiveness by the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>Where a drug or treatment has not been appraised by NICE, funding decisions should be made by the relevant National Health Service commissioner, based on an assessment of the available evidence and on the basis of an individual patient’s clinical circumstances.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/10/2017 15:57:33 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

759725

registered interest
date	12/09/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Benzodiazepines
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what data his Department collected on benzodiazepine dependence relating to 2016.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	10122
answer	answer is ministerial correction date of answer 09/10/2017 answer text <p>Data specific to this question is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2017 11:28:10 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750926

registered interest
date	11/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of drugs for the treatment and post-treatment needs of breast cancer patients contain lactose; and what provision is made for breast cancer patients who are intolerant or allergic to lactose.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4161
answer	answer is ministerial correction date of answer 17/07/2017 answer text <p>Lactose (milk sugar) is commonly used as a diluent in solid oral dosage forms such as tablets and capsules; however is rarely present in oral liquid presentations or parenteral dosage forms, such as injections. While no list of “lactose-free” medicines is maintained, the presence or absence of lactose in any licensed medicine, including those for breast cancer, can be readily identified.</p><p> </p><p>Where a medicine contains lactose, this is highlighted, together with the quantity of lactose, within the Summary of Product Characteristics. The package leaflet for that medicine will also highlight in qualitative terms whether the medicine contains lactose. The package leaflet is provided with each pack of medicine sold or dispensed in the United Kingdom.</p><p> </p><p>The British National Formulary, a standard medical text in the UK, advises that the lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However, in patients with severe lactose intolerance, lactose content should be determined before prescribing especially if they are taking several products containing lactose.</p><p> </p><p>Clinicians prescribe the medicines and drugs that are most appropriate for their patient, taking into account all relevant factors and guidance. The Medicines and Healthcare products Regulatory Agency, which is responsible for the regulation of medicines in the UK, will help prescribers to establish the availability of a lactose free version of any particular medicine.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/07/2017 15:49:05 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750163

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	GP Surgeries: Repairs and Maintenance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has carried out to ensure that the proposed £1,000 financial assistance offered to GP practices which accept the full repairing lease contract will be sufficient to cover the legal and survey work associated with those leases.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4033
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>The £1,000 + VAT offered to general practitioner practices is intended to assist with the legal fees associated with documenting a lease. The calculation is based on the fact that the ‘template’ lease has already been negotiated and agreed with NHS Property Services and the British Medical Association, which minimises negotiations with practices.</p><p> </p><p>The nature of lease – either Full Repairing and Insuring or Internal Repairs – determines the level of reimbursement for the current market rent. This includes both the lease rent and an element for upkeep of the tenanted areas. This is set out in the Premises Costs Directions 2013.</p><p> </p><p>Ultimately, it is for the landlord and tenant to agree the terms of any lease to suit their specific circumstances.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4036 question first answered 13/07/2017 13:05:44 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750164

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to review the Carr-Hill funding formula for GP practices with atypical populations.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4034
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England recognises that atypical practices with a significantly skewed patient population will not necessarily have their workload reflected through the Carr-Hill Formula. It is for this reason that NHS England is exploring the additional demands on atypical practices, testing out in the first instance, the experiences of practices that serve university populations, practices with significant number of non-English speaking patients, and practices operating within remote or isolated areas.</p><p> </p><p>Commissioner guidance was published in December 2016 and further analysis of the workload implications is being undertaken.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/07/2017 11:47:14 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750166

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	GP Surgeries: Repairs and Maintenance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on GP funding of the proposed full repairing leases offered to GP surgeries.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4036
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>The £1,000 + VAT offered to general practitioner practices is intended to assist with the legal fees associated with documenting a lease. The calculation is based on the fact that the ‘template’ lease has already been negotiated and agreed with NHS Property Services and the British Medical Association, which minimises negotiations with practices.</p><p> </p><p>The nature of lease – either Full Repairing and Insuring or Internal Repairs – determines the level of reimbursement for the current market rent. This includes both the lease rent and an element for upkeep of the tenanted areas. This is set out in the Premises Costs Directions 2013.</p><p> </p><p>Ultimately, it is for the landlord and tenant to agree the terms of any lease to suit their specific circumstances.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4033 question first answered 13/07/2017 13:05:44 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire